"Utilizing the latest in recombinant DNA technology, this segment develops plasma-based proteins and therapies for addressing bleeding disorders such as hemophilia, immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other bloodrelated conditions."